Brazilian aerospace group Embraer, which includes executive or business jets in its product portfolio, has announced that it has released technical information that will help users of these jets to optimise them for the transport of anti-Covid-19 vaccines. Currently, more than 1 400 Embraer executive jets are in operation in more than 70 countries, and operators are considering the possibility of using them to transport vaccines.

The documents that have been released cover all the group’s business jet types. These are the Phenom 100, Phenom 100EV, Phenom 300, Phenom 300E, Legacy 450, Legacy 500, Legacy 600, Legacy 650, Legacy 650E, Praetor 500, Praetor 600, Lineage 1000 and Lineage 1000E.

“Embraer is deeply engaged in the fight against Covid-19, providing technical information to customers in many segments, always with the main goal of supporting and enhancing our customers’ operations,” affirmed Embraer Technical Services & Product Support VP Sérgio Cunha. “This technical information will help customers to develop their procedures in order to carry a large amount of Covid-19 vaccines.”

Before releasing the information, the company undertook tests and simulations to clearly establish the vaccine transport technical specifications, as well as payload requirements. Vaccine transport has to be done at low temperatures, which are obtained by using dry ice (solid carbon dioxide).

The release of the technical information necessary to allow its business jets to carry vaccines followed the release of the equivalent technical information permitting its commercial jets to transport vaccines. That information was released in December. 

Embraer has also authorised the use of two long-lasting anti-bacterial, anti-viral and anti-microbe coating systems, for application to its aircraft cabin surfaces. These are MicroShield360 and Bacoban. Further, it has issued guidance on the use of ultraviolet C (better known as UVC) lights to sanitise aircraft cockpits.